Baclovir Tablet 250 mg (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir orally at a dose of 250 mg 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes Adults: Administer this drug orally at a dose of 250 mg 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Administer this drug orally at a dose of 125 mg twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this drug orally at a dose of 250 mg twice daily. Discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: As creatinine clearance of this drug is reduced in patients with renal impairment, adjust the dose with caution. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and initial genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose, twice daily 10～29 250 mg per dose, once daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59 125 mg per dose, twice daily 10～29 125 mg per dose, once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose, twice daily 10～29 125 mg per dose, twice daily 4) If only serum creatinine is known, creatinine clearance may be calculated using the following formula. Men: {weight(kg) × (140-age)}/ {72 × serum creatinine(mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, administration every 48 hours is recommended, taking the dialysis interval into account. As 4 hours of hemodialysis reduces plasma concentrations of this drug by approximately 75%, administer this drug immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary for patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This medication should not be used in certain patients. First, patients who have had an allergic reaction to this medication or its components should not take it. Also, since this medication contains lactose, patients with genetic issues such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should avoid using it. Patients with kidney function issues should be more cautious when using this medication, and dosage adjustment may be necessary. Mild symptoms such as headache or nausea may appear while taking this medication, but these are common side effects. Rarely, hematological abnormalities such as thrombocytopenia or leukopenia have been reported, and neurological symptoms such as dizziness, drowsiness, or hallucinations may also occur. In the gastrointestinal system, nausea, vomiting, abdominal pain, and diarrhea may frequently occur, and liver function abnormalities or jaundice have been reported rarely. Skin reactions such as rash, itching, urticaria, or swelling around the face or eyes may occur, and very rarely, serious skin reactions may occur. Patients with poor kidney function should be cautious as the risk of acute renal failure may increase. This medication does not completely cure genital herpes and it is important to follow safe practices during sexual intercourse due to the possibility of transmitting the infection even during treatment. There is no special impact when driving or operating machinery; however, caution is necessary if symptoms such as dizziness or drowsiness occur. Elderly patients generally do not require dose adjustments; however, if kidney function is decreased, dose adjustment may be necessary. In case of overdose, immediate medical attention should be sought for appropriate treatment, and blood dialysis may be helpful. This medication should be stored in a dry place below 30℃ and kept in a secure location out of reach of children. Additionally, transferring to another container can be detrimental to maintaining quality.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucination
• palpitations

This medication should be stored in a sealed container to avoid exposure to air or moisture and should be kept in a cool, dry place below 30 degrees. Proper storage can help maintain the medication's efficacy.

Appearance

White round film-coated tablet

Package unit

21 tablets (7 tablets/PTP X 3)